Verition Fund Management LLC Atea Pharmaceuticals, Inc. Transaction History
Verition Fund Management LLC
- $16.5 Billion
- Q2 2024
A detailed history of Verition Fund Management LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 65,976 shares of AVIR stock, worth $216,401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,976Holding current value
$216,401% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding AVIR
# of Institutions
110Shares Held
51.2MCall Options Held
71.8KPut Options Held
318K-
Black Rock Inc. New York, NY9.12MShares$29.9 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.38MShares$20.9 Million15.06% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$17.8 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$15.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.48MShares$14.7 Million1.81% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $273M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...